TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05874882

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash as adjunct to scaling and root planing in periodontitis patients
Description: patients with periodontitis will receive scaling and rootplaning and a placebo mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
Study: NCT05237843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Besides anti-thrombotic effects, hydroxychloroquine have immunoregulatory properties and can block the production of pro-inflammatory cytokines ( Mekinian A et al ,2015 ) , Few in vitro studies showed a potential benefit of hydroxychloroquine in early trophoblastic migration and implantation. Hydroxychloroquine restored trophoblastic fusion and differentiation and restored the annexin A5 expression.( Guller S et al ,2011 )
Study: NCT05184452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1.4g, IV)
Description: VRC07-523LS 1.4g administered via IV infusion
Study: NCT04807335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT001
Description: nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: iv single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: iv single dose
Study: NCT04694027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: omega 3 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VitaE
Description: vitamin e 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VitaE
Description: vitamin e 400 mg
Study: NCT04870125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)
Description: Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Medical air
Description: Inhaled Medical Air for up to 90 minutes daily for 3 days.
Study: NCT06324396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)
Description: A single oral dose of sildenafil will be administered to all study subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
Description: A single oral dose of pravastatin will be administered to all study subjects.
Study: NCT05347706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula
Description: Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula
Description: Enteral feeding is started with in the first 24 hours of life. Human milk is encouraged, and preterm formula is fed when human milk is not available due to mother's or family's condition. Patients with feeding intolerance are temporarily fed with AAF or EHF instead of human milk or preterm formula. Once the patients with feeding intolerance show clinical improvement, AAF or EHF feeding is discontinued, and the previous feeding, either human milk or preterm formula is resumed
Study: NCT04637087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation risk electronic health record alert
Description: Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
Study: NCT05248685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual CD33/CLL1 CAR T
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
Study: NCT05643794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive rozanolixizumab during the dosing periods as pre-defined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive rozanolixizumab during the dosing periods as pre-defined.
Study: NCT05433922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: cyclosporine in combination with Avatrombopag to treat
Study: NCT05909384

Intervention type: OTHER
Intervention: Survey
Description: Multiple rounds of surveys collecting information on sepsis diagnosis and management in resource-limited settings.
Study: NCT05643794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive Placebo during the dosing periods as pre-defined.
Study: NCT05769205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI with contrast
Study: NCT05705362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simple Crossover
Description: Regardless of allocated arms, stent implantation in the MV (selected 1:1 according to the distal MV size) followed by systematic proximal optimization technique (POT, post-dilatation of the stent at the level of proximal MV with a balloon diameter sized 1:1 according to the proximal MV) or POT like procedure is strongly recommended.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Side branch opening
Description: According to the latest European Bifurcation Club (EBC) consensus document, distal SB rewiring followed by kissing balloon inflation (eventually conducted with short non-compliant balloons) and repeat POT procedures are highly recommended. An additional stent will be allowed if major dissection or decreased TIMI flow of SB occurs during SB treatment.
Study: NCT05973253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prepared drop of medroxy progestrone acetat 1%
Description: In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
Study: NCT05322720

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EOC202
Description: EOC202 will be SC injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel will be Iv injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: albumin-bound paclitaxel will be Iv injection
Study: NCT05184452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (1.4g, SC)
Description: VRC07-523LS 1.4g administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (40mg/kg, IV)
Description: VRC07-523LS 40mg/kg administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (20mg/kg, IV)
Description: PGT121.414.LS 20mg/kg administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (20mg/kg, SC)
Description: PGT121.414.LS 20mg/kg administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (1.4g, IV)
Description: PGT121.414.LS 1.4g administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (1.4g, SC)
Description: PGT121.414.LS 1.4g administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (40mg/kg, IV)
Description: PGT121.414.LS 40mg/kg administered via IV infusion
Study: NCT06404918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane group
Description: The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane group
Description: Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
Study: NCT05643794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive Placebo during the dosing periods as pre-defined.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive Placebo during the dosing periods as pre-defined.
Study: NCT06145009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Limit food intake to 10 hours per day as described in the experimental arm section.
Study: NCT05054738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Recovery Program
Description: A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Recovery Program
Description: A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stable & Able (S&A)
Description: A 90-day Home Telehealth program designed to help maintain skills to stay sober.
Study: NCT05817929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 5 ml blood sample will be withdrawn at the surgery start and at the surgery end
Study: NCT05632094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
Study: NCT04917276

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cell
Description: Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cell
Description: Detecting CTC in different time points of treatment (like PR, PD, pre and post-operation)
Study: NCT05328830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization
Description: Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller
Description: Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
Study: NCT05721274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilization and Conditional community incentives
Description: Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
Study: NCT06362135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Home Visit
Description: The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned.
Study: NCT06199284

Intervention type: DEVICE
Group type: OTHER
Intervention: Atalante exoskeleton
Description: The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
Study: NCT06094881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection [Gazyva]
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Study: NCT05544500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Gum
Description: Functional gum containing a proprietary composition of a herbal extract and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Basic Chewing Gum
Description: Sugar-free chewing gum
Study: NCT05383612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Warm compresses
Description: Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol Sodium Eye Drops
Description: 3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Diquafosol Sodium Eye Drops
Description: 3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
Study: NCT05628831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES suspension with autologous tissue
Description: Autologous tissue will be fixated on solid points in pelvis using vNOTES.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal surgery
Description: Vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Uterosacral and cardinal ligaments will be repositioned and attached to the vaginal vault after hysterectomy at the time of vault closure. A modified McCall culdoplasty will be done in this group to prevent enterocele and further apical prolapse
Study: NCT04789551

Intervention type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected

Intervention type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected

Intervention type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected
Study: NCT06368011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy
Description: Psychoeducation was delivered in 8 sessions lasting 90 minutes to two separate groups of 8-10 individuals in the experimental group.Group sessions were conducted once a week at the community mental health center under the leadership of the researcher.In total, the psychoeducation lasted 10 weeks, including make-up sessions.
Study: NCT06575582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support from Digital Navigators to Treatment Team
Description: The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support from Digital Navigators to Patients
Description: The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Digital Navigators
Description: The training takes place in the six study centers and is preferably aimed at medical assistants.
Study: NCT05262387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 50% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 100% basal rate reduction
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 100% basal rate reduction
Description: Administered SC.
Study: NCT04925063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Study: NCT05016232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP N' Shine: Strength Based Case Management (Stage 1)
Description: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)
Description: 1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist.
Study: NCT06219460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation using two types of face masks
Description: ventilation using two types of face mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation using two types of face masks
Description: ventilation using two types of face mask
Study: NCT06148922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Mental Health First Aid Workshop
Description: a 2-hour workshop delivered by a registered nurse with a MHFA training certificate

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interviews
Description: One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.